(Q47687470)

4 February 2018

review article

1 reference

title

Medical therapy of active Crohn's disease (English)

1 reference

4 February 2018

author name string

Järnerot G

series ordinal

1

1 reference

4 February 2018

Sandberg-Gertzén H

series ordinal

2

1 reference

4 February 2018

Tysk C

series ordinal

3

1 reference

4 February 2018

publication date

1 March 1998

1 reference

4 February 2018

Bailliere's clinical gastroenterology

published in

1 reference

4 February 2018

volume

12

1 reference

4 February 2018

issue

1

1 reference

4 February 2018

page(s)

73-92

1 reference

4 February 2018

Cyclosporin for Crohn's disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Low-dose oral methotrexate in refractory inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

A controlled double blind study of azathioprine in the management of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Hyperbaric oxygenation in severe perineal Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Sulphadoxine-pyrimethamine therapy in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Low-Dose Cyclosporine for the Treatment of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Methotrexate for the Treatment of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Review article: immunosuppressive therapy for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

The effect of metronidazole and sulfasalazine on the fecal flora in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Relation between concentrations of metronidazole and Bacteroides spp in faeces of patients with Crohn's disease and healthy individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Hyperbaric oxygen for perianal Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Methotrexate for the treatment of refractory Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

New steroids for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Frequency of glucocorticoid resistance and dependency in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Efficacy of cyclosporine in treatment of fistula of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Controlled trial of azathioprine in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn disease. A double-blind, randomized, multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Rifabutin and ethambutol do not help recurrent Crohn's disease in the neoterminal ileum

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

A comparison of budesonide with prednisolone for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Neurophysiologic Studies of Patients with Crohn's Disease on Long-Term Treatment with Metronidazole

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Double blind, placebo controlled trial of metronidazole in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

Controlled trial of azathioprine in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990086-0

7 January 2021

10.1016/S0950-3528(98)90086-0

Identifiers

DOI

1 reference

4 February 2018

1 reference

4 February 2018